GlassScriptPhysician profile
Arthur Lowy
NPI 1396707931
$4,168.38
in general payments reported to CMS, 2019-2025
30 companies · $1,006 in 2025
The $1,006 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $405 · 2020: $226 · 2021: $507 · 2022: $744 · 2023: $454 · 2024: $827 · 2025: $1,006.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,286.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $632.64 | 2020-2022 | |
| Abbvie INC. | $581.68 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $528.02 | 2019-2025 | Xifaxan |
| Janssen Biotech, INC. | $372.08 | 2019-2025 | Tremfya, Stelara |
| Novo Nordisk INC | $314.59 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Intercept Pharmaceuticals, INC. | $272.23 | 2022-2023 | Ocaliva |
| Pfizer INC. | $221.11 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $163.56 | 2024-2025 | Voquezna |
| Daiichi Sankyo INC. | $157.28 | 2019-2023 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $102.98 | 2024-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $81.05 | 2019-2025 | Entyvio, Eohilia |
| Ardelyx, INC. | $78.97 | 2024-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $76.91 | 2022-2023 | Belsomra |
| Evoke Pharma, INC. | $70.96 | 2022-2025 | |
| Redhill Biopharma INC. | $69.40 | 2020-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $54.33 | 2025 | Watchman Flx |
| Braintree Laboratories, INC. | $50.35 | 2023-2024 | Sutab, Suflave |
| Exact Sciences Corporation | $49.19 | 2024-2025 | Cologuard Collection Kit |
| Celgene Corporation | $46.52 | 2021 | |
| Eisai INC. | $33.94 | 2020 | |
| Madrigal Pharmaceuticals | $33.03 | 2025 | Rezdiffra |
| Allergan, INC. | $28.42 | 2019 | |
| Lundbeck LLC | $27.09 | 2024 | Rexulti |
| Ferring Pharmaceuticals INC. | $24.99 | 2020 | |
| Sanofi-Aventis U.S. LLC | $22.13 | 2023 | |
| Lilly USA, LLC | $18.98 | 2024 | Jardiance |
| Shire North American Group INC | $17.86 | 2019 | |
| Ironwood Pharmaceuticals, INC | $13.27 | 2022 | |
| Esperion Therapeutics, INC. | $12.62 | 2021 | |
| Hikma Pharmaceuticals USA | $12.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Lowy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.